Carnitine Palmitoyltransferase System: A New Target for Anti-Inflammatory and Anticancer Therapy?
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanisms and preclinical literature without systematic search methodology
PubMed 34764874 · doi:10.3389/fphar.2021.760581
What was done
The authors synthesized literature on the structure, tissue distribution, and physiological functions of the carnitine palmitoyltransferase (CPT) system in fatty acid oxidation. They reviewed its involvement in immune homeostasis, cancer, and acute and chronic inflammatory diseases (including COPD, asthma, acute lung injury, chronic granulomatous disease, nonalcoholic fatty liver disease, hepatic ischemia-reperfusion injury, kidney fibrosis, acute kidney injury, and cardiovascular disorders), and reviewed preclinical and clinical modulators ranging from traditional medicines to nanodevices.
What was found
The abstract reports no quantitative data or effect sizes. It qualitatively reports that disruption of CPT activity contributes to metabolic disturbance, oxidative damage, and inflammation in multiple organ systems, and notes that while numerous CPT agonists and antagonists have been evaluated preclinically, very few have transitioned into clinical practice.
Why it matters
Modulating CPT-dependent fatty acid oxidation offers a potential pharmacological approach to regulate immune responses and tumor metabolism across a broad spectrum of diseases.
Limits
The paper is a non-systematic narrative review providing broad descriptive claims rather than new empirical data. The abstract provides no quantitative outcomes, details on search strategy, or evaluation of clinical trial safety and efficacy.
Cited by
- supports Carnitine palmitoyltransferase (CPT) acts as the critical gatekeeper enzyme transporting fatty acids into the mitochondria for oxidation.